Patents by Inventor Mihalis S. Kariolis
Mihalis S. Kariolis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11884944Abstract: Provided herein are proteins, which are capable of being transported across the blood-brain barrier (BBB) and comprise sulfoglucosamine sulfohydrolase (SGSH) enzyme-Fc fusion polypeptides. Certain embodiments also provide methods of using such proteins to treat Sanfilippo syndrome A.Type: GrantFiled: June 30, 2022Date of Patent: January 30, 2024Assignee: DENALI THERAPEUTICS INC.Inventors: Tina Giese, Gunasekaran Kannan, Mihalis S. Kariolis, Cathal S. Mahon
-
Patent number: 11866742Abstract: Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder. Methods for transporting agents across the blood-brain barrier are also provided herein.Type: GrantFiled: November 23, 2020Date of Patent: January 9, 2024Assignee: DENALI THERAPEUTICS INC.Inventors: Anastasia Henry, Mihalis S. Kariolis, Cathal S. Mahon, Adam P. Silverman, Ankita Srivastava, Julie Ullman
-
Publication number: 20230227523Abstract: The present disclosure presents a general approach to engineering existing protein-protein interactions through domain addition and evolution. The disclosure teaches the creation of novel fusion proteins that include knottin peptides where a portion of the knottin peptide is replaced with a sequence that has been created for binding to a particular target. Such fusion proteins can also be bispecific or multi specific in that they can bind to and/or inhibit two or more receptors or receptor ligands. Knottins may be fused with an existing ligand (or receptor) as a general platform tor increasing the affinity of a ligand-receptor interaction or for creating a multi specific protein. In addition, the fusion proteins may comprise a knottin peptide fused to another protein where the other protein facilitates proper expression and folding of the knottin.Type: ApplicationFiled: November 14, 2022Publication date: July 20, 2023Inventors: Jennifer R. Cochran, Douglas S. Jones, Mihalis S. Kariolis, Ping-Chuan Tsai
-
Publication number: 20230131056Abstract: The invention is directed to novel sPD-1 variant-Fc fusion proteins.Type: ApplicationFiled: October 10, 2022Publication date: April 27, 2023Applicants: The Board of Trustees of the Leland Stanford Junior University, AKSO Biopharmaceutical, Inc.Inventors: Amato J. Giaccia, Todd A. Aguilera, Mihalis S. Kariolis, Yu Miao, Kaushik Thakkar, Xin Eric Zhang
-
Publication number: 20220378873Abstract: Provided herein are compositions and methods for alleviating cancer or infection in a subject by administering a therapeutically effective amount of a pharmaceutical composition comprising an isolated PD-1 variant polypeptide. The PD-1 variant polypeptide can inhibit the activity of PD-1 by, for example, competitive or non-competitive inhibition of the interaction between wild-type PD-1 and one or more of its ligands, PD-L1 and PD-L2.Type: ApplicationFiled: June 24, 2022Publication date: December 1, 2022Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Amato J. GIACCIA, Mihalis S. KARIOLIS, Todd A. AGUILERA
-
Patent number: 11498955Abstract: The invention is directed to novel sPD-1 variant—Fc fusion proteins.Type: GrantFiled: September 12, 2019Date of Patent: November 15, 2022Assignees: The Board of Trustees of the Leland Stanford Junior University, AKSO Biopharmaceutical, Inc.Inventors: Amato J. Giaccia, Todd A. Aguilera, Mihalis S. Kariolis, Yu Miao, Kaushik Thakkar, Xin Eric Zhang
-
Patent number: 11498952Abstract: The present disclosure presents a general approach to engineering existing protein-protein interactions through domain addition and evolution. The disclosure teaches the creation of novel fusion proteins that include knottin peptides where a portion of the knottin peptide is replaced with a sequence that has been created for binding to a particular target. Such fusion proteins can also be bispecific or multi specific in that they can bind to and/or inhibit two or more receptors or receptor ligands. Knottins may be fused with an existing ligand (or receptor) as a general platform tor increasing the affinity of a ligand-receptor interaction or for creating a multi specific protein. In addition, the fusion proteins may comprise a knottin peptide fused to another protein where the other protein facilitates proper expression and folding of the knottin.Type: GrantFiled: October 8, 2020Date of Patent: November 15, 2022Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jennifer R. Cochran, Douglas S. Jones, Mihalis S. Kariolis, Ping-Chuan Tsai
-
Patent number: 11400133Abstract: Provided herein are compositions and methods for alleviating cancer or infection in a subject by administering a therapeutically effective amount of a pharmaceutical composition comprising an isolated PD-1 variant polypeptide. The PD-1 variant polypeptide can inhibit the activity of PD-1 by, for example, competitive or non-competitive inhibition of the interaction between wild-type PD-1 and one or more of its ligands, PD-L1 and PD-L2.Type: GrantFiled: February 7, 2020Date of Patent: August 2, 2022Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Amato J. Giaccia, Mihalis S. Kariolis, Todd A. Aguilera
-
Patent number: 11124567Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.Type: GrantFiled: January 15, 2021Date of Patent: September 21, 2021Assignee: Denali Therapeutics Inc.Inventors: Mark S. Dennis, Zhenyu Gu, Mihalis S. Kariolis, Cathal S. Mahon, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Adam P. Silverman, Bettina Van Lengerich
-
Publication number: 20210214438Abstract: In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.Type: ApplicationFiled: January 15, 2021Publication date: July 15, 2021Applicant: Denali Therapeutics Inc.Inventors: Mark S. Dennis, Zhenyu Gu, Mihalis S. Kariolis, Cathal S. Mahon, Kathryn M. Monroe, Joshua I. Park, Rachel Prorok, Adam P. Silverman, Bettina Van Lengerich
-
Publication number: 20210206824Abstract: The present disclosure presents a general approach to engineering existing protein-protein interactions through domain addition and evolution. The disclosure teaches the creation of novel fusion proteins that include knottin peptides where a portion of the knottin peptide is replaced with a sequence that has been created for binding to a particular target. Such fusion proteins can also be bispecific or multi specific in that they can bind to and/or inhibit two or more receptors or receptor ligands. Knottins may be fused with an existing ligand (or receptor) as a general platform tor increasing the affinity of a ligand-receptor interaction or for creating a multi specific protein. In addition, the fusion proteins may comprise a knottin peptide fused to another protein where the other protein facilitates proper expression and folding of the knottin.Type: ApplicationFiled: October 8, 2020Publication date: July 8, 2021Inventors: Jennifer R. Cochran, Douglas S. Jones, Mihalis S. Kariolis, Ping-Chuan Tsai
-
Patent number: 10844106Abstract: The present disclosure presents a general approach to engineering existing protein-protein interactions through domain addition and evolution. The disclosure teaches the creation of novel fusion proteins that include knottin peptides where a portion of the knottin peptide is replaced with a sequence that has been created for binding to a particular target. Such fusion proteins can also be bispecific or multi specific in that they can bind to and/or inhibit two or more receptors or receptor ligands. Knottins may be fused with an existing ligand (or receptor) as a general platform for increasing the affinity of a ligand-receptor interaction or for creating a multi specific protein. In addition, the fusion proteins may comprise a knottin peptide fused to another protein where the other protein facilitates proper expression and folding of the knottin.Type: GrantFiled: November 7, 2011Date of Patent: November 24, 2020Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jennifer R. Cochran, Douglas S. Jones, Mihalis S. Kariolis, Ping-Chuan Tsai
-
Publication number: 20200360474Abstract: Provided herein are compositions and methods for alleviating cancer or infection in a subject by administering a therapeutically effective amount of a pharmaceutical composition comprising an isolated PD-1 variant polypeptide. The PD-1 variant polypeptide can inhibit the activity of PD-1 by, for example, competitive or non-competitive inhibition of the interaction between wild-type PD-1 and one or more of its ligands, PD-L1 and PD-L2.Type: ApplicationFiled: February 7, 2020Publication date: November 19, 2020Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Amato J. Giaccia, Mihalis S. Kariolis, Todd A. Aguilera
-
Publication number: 20200181231Abstract: The invention is directed to novel sPD-1 variant—Fc fusion proteins.Type: ApplicationFiled: September 12, 2019Publication date: June 11, 2020Applicants: The Board of Trustees of the Leland Stanford Junior University, AKSO Biopharmaceutical, Inc.Inventors: Amato J. Giaccia, Todd A. Aguilera, Mihalis S. Kariolis, Yu Miao, Kaushik Thakkar, Xin Eric Zhang
-
Patent number: 10588938Abstract: Provided herein are compositions and methods for alleviating cancer or infection in a subject by administering a therapeutically effective amount of a pharmaceutical composition comprising an isolated PD-1 variant polypeptide. The PD-1 variant polypeptide can inhibit the activity of PD-1 by, for example, competitive or non-competitive inhibition of the interaction between wild-type PD-1 and one or more of its ligands, PD-L1 and PD-L2.Type: GrantFiled: October 2, 2017Date of Patent: March 17, 2020Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Amato J. Giaccia, Mihalis S. Kariolis, Todd A. Aguilera
-
Publication number: 20180125934Abstract: Provided herein are compositions and methods for alleviating cancer or infection in a subject by administering a therapeutically effective amount of a pharmaceutical composition comprising an isolated PD-1 variant polypeptide. The PD-1 variant polypeptide can inhibit the activity of PD-1 by, for example, competitive or non-competitive inhibition of the interaction between wild-type PD-1 and one or more of its ligands, PD-L1 and PD-L2.Type: ApplicationFiled: October 2, 2017Publication date: May 10, 2018Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Amato J. Giaccia, Mihalis S. Kariolis, Todd A. Aguilera
-
Patent number: 8778888Abstract: Disclosed are peptides having a cystine knot structural motif and comprising a sequence engineered for specificity against ?IIb?3 integrin, found on platelets, and a method of using the same in anti-thrombotic therapies. The present peptides utilize a cystine knot scaffold derived from modified agouti-related protein or agatoxin, An alternate library screening strategy was used to isolate variants of peptides that selectively bound to ?IIb?3 integrin or to both ?IIb?3 and ?V?3 integrins. Unique consensus sequences were identified within the identified peptides suggesting alternative molecular recognition events that dictate different integrin binding specificities. In addition, the engineered peptides prevented human platelet aggregation in a plasma-based assay and showed high binding affinity for ?IIb?3 integrin.Type: GrantFiled: November 2, 2010Date of Patent: July 15, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jennifer R. Cochran, Adam P. Silverman, Mihalis S. Kariolis
-
Publication number: 20140073518Abstract: The present disclosure presents a general approach to engineering existing protein-protein interactions through domain addition and evolution. The disclosure teaches the creation of novel fusion proteins that include knottin peptides where a portion of the knottin peptide is replaced with a sequence that has been created for binding to a particular target. Such fusion proteins can also be bispecific or multi specific in that they can bind to and/or inhibit two or more receptors or receptor ligands. Knottins may be fused with an existing ligand (or receptor) as a general platform for increasing the affinity of a ligand-receptor interaction or for creating a multi specific protein. In addition, the fusion proteins may comprise a knottin peptide fused to another protein where the other protein facilitates proper expression and folding of the knottin.Type: ApplicationFiled: November 7, 2011Publication date: March 13, 2014Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jennifer R. Cochran, Douglas S. Jones, Mihalis S. Kariolis, Ping-Chuan Tsai
-
Publication number: 20110136740Abstract: Disclosed are peptides having a cystine knot structural motif and comprising a sequence engineered for specificity against ?IIb?3 integrin, found on platelets, and a method of using the same in anti-thrombotic therapies. The present peptides utilize a cystine knot scaffold derived from modified agouti-related protein or agatoxin, An alternate library screening strategy was used to isolate variants of peptides that selectively bound to ?IIb?3 integrin or to both ?IIb?3 and ?V?3 integrins. Unique consensus sequences were identified within the identified peptides suggesting alternative molecular recognition events that dictate different integrin binding specificities. In addition, the engineered peptides prevented human platelet aggregation in a plasma-based assay and showed high binding affinity for ?IIb?3 integrin.Type: ApplicationFiled: November 2, 2010Publication date: June 9, 2011Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jennifer R. Cochran, Adam P. Silverman, Mihalis S. Kariolis